Illumina, Inc. (ILMN) Stock Price & Analysis
Illumina, Inc. (ILMN) fell 1.55% to USD 218.22 as of September 8, 2026 at 02:52 UTC, according to Nexqual real-time market data.
ILMN last closed at USD 218.22; the session ranged USD 213.95–219.58 on volume of 1,748,198 shares. Market capitalization is —, with a 52-week range of USD 88–231.81 (NMS). Source: Nexqual, September 8, 2026 at 02:52 UTC.
Key Statistics (as of September 8, 2026 at 02:52 UTC)
| Price | USD 218.22 |
|---|---|
| Change | ▼ 1.55% (down) |
| Previous Close | USD 218.22 |
| Open | USD 218.22 |
| Day Range | USD 213.95 – 219.58 |
| 52-Week Range | USD 88 – 231.81 |
| Volume | 1,748,198 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (ILMN)
Nexqual's technical model rates ILMN "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 02:52 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 58.15 (neutral) |
| vs SMA50 | Above (USD 198.18) |
| MACD | 6.77 (positive) |
From Illumina, Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
- The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
- It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services.
- The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.
Partnerships
- It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | USD 827.72 | ▼ 2.85% |
| VRTX | Vertex Pharmaceuticals Incorpor | USD 546.12 | ▼ 1.91% |
| BIIB | Biogen Inc. | USD 220.83 | ▼ 0.83% |
| ISRG | Intuitive Surgical, Inc. | USD 366.7 | ▼ 1.39% |
| CRSP | CRISPR Therapeutics AG | USD 55.79 | ▼ 1.99% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 02:52 UTC. This page is informational and not investment advice.